KeViRx, Inc.

KeViRx, Inc. is a Charlottesville, Virginia-based biotechnology company founded in 2016 that focuses on the development of small molecule therapeutics for treating microvascular leakage and inflammation. The company's platform technology, centered on its lead asset KVX-053, is designed to heal the endothelial lining within blood vessels and regenerate lung cell connections. Unlike conventional treatments that target specific pathogens, KeViRx’s approach is host-directed, aiming to address the underlying cellular damage that contributes to acute lung injury, which can be caused by viral infections, sepsis, bacterial pneumonia, or chemical inhalation.

This technology is critical for patients in intensive care settings who may otherwise rely on mechanical ventilation, which can exacerbate lung damage. By repairing the root causes of inflammation and restoring lung function, KVX-053 aims to improve patient recovery and reduce reliance on invasive respiratory support. The company’s research has shown efficacy in various preclinical models of lung injury and cancer. Supported by non-dilutive funding, including grants from the U.S. Department of Defense and membership in the Blue Knight collaboration, KeViRx is actively advancing its lead compound toward clinical trials.